Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
.11 and Up!
»
ACTC
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by IMAKEMONEY: [QB] Related Quotes Sym. Price Chg. ACTC Trade News 0.69 0.05 Investor`s Business Daily Cites Advanced Cell Technology`s Scientific Leadership in Burgeoning Embryonic Stem Cell Industry October 06, 2006 06:30:16 (ET) ALAMEDA, Calif., Oct 06, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that the Company was prominently featured by the newspaper "Investor's Business Daily" in an in-depth article highlighting top investment opportunities in the embryonic stem cell industry. The Investor's Business Daily (IBD) article, titled "Patience an Asset in Stem Cell Work," details the current political and ethical debates limiting federal funding for stem cell research and development. The IBD newspaper suggests that Advanced Cell Technology's (ACTC) groundbreaking science and research may help speed the development of stem cell-based cures by addressing some of these scientific and ethical debates. ACTC recently announced that Company scientists demonstrated the ability to generate new human embryonic stem cell lines by adapting a proven technique used at in vitro fertilization labs to determine genetic health. The ACTC approach maintains the embryo's potential for life, addressing one of the key debates in stem cell research by showing it is possible to generate embryonic stem cell lines without harming embryos. ACTC has said its non-destructive technique may help open up the federal funding and speed the development of needed stem cell-based science and breakthrough therapies, according to the IBD article. To accelerate its development programs, the article noted that ACTC recently moved to California where "voters approved a 10-year, $3 billion stem cell research fund in 2004." "If you're going to survive you must be close to the capital," the article quoted William Caldwell IV, Chief Executive Officer of Advanced Cell Technology. To read the entire article, please visit http://www.investors.com/editorial/IBDArticles.asp?artsec=22&issue=200 60929&view=1 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) About Advanced Cell Technology, Inc. Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: [URL=http://www.advancedcell.com.]www.advancedcell.com.[/URL] For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/advanced_cell. To read or download Advanced Cell's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/advanced_cell/factsheet.html. To view recent stock quotes and news, visit http://www.trilogy-capital.com/tcp/advanced_cell/quote.html. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2006. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. SOURCE: Advanced Cell Technology, Inc. Financial Dynamics Robert Stanislaro, 212-850-5657 (Media) or The Investor Relations Group James Carbonara, 212-825-3210 (Investors) or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com Copyright Business Wire 2006 [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2